Diffuse hombe B-cell lymphoma (DBCL), NOS, GCB subtype, primary central central nervous system lymphoma-01

Muna Zvita 2019, VaWang, mudzidzisi wekuNortheast China, vakatanga kurwadziwa nemusoro. Musi waZvita 19, 2019, bvunzo dzekuongorora dzakaratidza zvinotevera: PET-CT yakaratidza density mumvuri ine yakawedzera zvakanyanya FDG metabolism kuruboshwe rwemberi lobe uye corpus callosum ibvi nzvimbo (inenge 3.4 * 1.9 cm, SUVmax = 34.4). Biopsy uye immunohistochemistry yakasimbisa kupararira hombe B-cell lymphoma (DLBCL, NOS, GCB subtype), ine immunophenotype inoratidza Ki67(50%+), CD19(+), CD20(+), PAX5(+), CD79(+), MUM1(+), BCL(+), CD10(-/+), CD2(diki+). Cerebrospinal fluid analysis yakaratidza 6% immature lymphoid masero ane morphological variability. Kuongororwa kwaive kwekutanga central central nervous system lymphoma (DLBCL, GCB subtype).

Mushure mekutsvaga nzira dzekurapa pamhepo, VaWang vakadzidza nezve Lu Dao Pei Hospital's immunotherapy kugona uye nekukurumidza vakatsvaga hunyanzvi hwavo. Zvichitevera kuongororwa kwemuviri uye kuongororwa zvine hungwaru nechikwata chenyanzvi dzechipatara, zvakasarudzwa kuti VaWang vapinde muchirongwa chekiriniki chekurapa kweCART, kunyanya vachishandisa CD19 CART masero. Akagamuchira autologous CD19 CAR-T cell infusion musi wa24 Kubvumbi, 2023. Pakazosvika Chikunguru 30, 2023, akaongororwa kuti akange awana kuregererwa kwakakwana (CR) uye kubva adzokera kuhupenyu hwemazuva ese.